Abstract
Summary
We provide an update on how commonly prescribed osteoporosis therapies are being initiated in older adults in Ontario. Patients newly prescribed denosumab are older, more often female, and have more comorbidities than those prescribed bisphosphonates. Their characteristics, monitoring, and persistence with prescribed therapy differ from clinical trial participants. Real-world studies on oral bisphosphonates and denosumab might be valuable.
Purpose
To provide a contemporary view on oral bisphosphonate and denosumab prescribing to older adults in routine care.
Methods
Using linked healthcare databases, we conducted a population-based cohort study of adults ≥ 66 years newly prescribed oral bisphosphonates or denosumab between February 2013 and March 2017 in Ontario, Canada. We captured their clinical characteristics, monitoring, and continuous use of prescribed therapies. We illustrate how “real-world” new users of bisphosphonates and denosumab differ from randomized controlled trial (RCT) participants.
Results
There were 107,847 individuals newly prescribed oral bisphosphonates (n = 59,996) or denosumab (n = 47,851) over the study period. Compared with new users of oral bisphosphonates, denosumab users were older (mean age 79.1 vs. 75.7 years), more often female (97.2 vs. 71.8%), from non-rural areas (93.9 vs. 89.9%), and resided in long-term care (10.9 vs. 3.3%). They had more comorbidities including dementia, falls, and fractures.
Following their new prescription, denosumab users had more frequent testing of serum calcium. Duration of continuous use of denosumab was longer than bisphosphonates, and more bisphosphonate users had evidence of treatment discontinuation (56.7 bisphosphonate vs. 33.8% denosumab users discontinued therapy at 365 days). Compared with RCT participants, a higher proportion of “real-world” bisphosphonate and denosumab users had comorbidities including advanced kidney disease.
Conclusion
The clinical characteristics and monitoring of new users of bisphosphonates and denosumab generally align with practice guidelines, product monographs, and drug reimbursement criteria. Given differences between real-world users and RCT participants, there may be a role for safety and effectiveness studies of bisphosphonates and denosumab in routine care.
Similar content being viewed by others
Availability of data and material
The analysis was conducted by members of the ICES Western facility (London, Ontario). Alexandra Ouédraogo and Dr. Kristin Clemens are responsible for the data analysis. The protocol can be obtained by emailing Dr. Kristin Clemens at Kristin.Clemens@sjhc.london.on.ca.
References
Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23:1075–1082. https://doi.org/10.1007/s00198-011-1645-7
Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM (2019) Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int 30:1865–1872. https://doi.org/10.1007/s00198-019-05051-1
Get coverage for prescription drugs | Ontario.ca. https://www.ontario.ca/page/get-coverage-prescription-drugs. Accessed 26 Jun 2020
Formulary Search. https://www.formulary.health.gov.on.ca/formulary/. Accessed 31 Mar 2020
Hayes KN, Ban JK, Athanasiadis G, Burden AM, Cadarette SM (2019) Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes. Osteoporos Int 30:2311–2319. https://doi.org/10.1007/s00198-019-05061-z
Jain S, Upadhyaya P, Goyal J et al (2015) A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspect Clin Res 6:86–90. https://doi.org/10.4103/2229-3485.154005
Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532. https://doi.org/10.1136/bmj.k3532
Matheson FI, Dunn JR, Smith KLW et al (2012) Development of the Canadian Marginalization index: a new tool for the study of inequality. Can J Public Health 103:3–5. https://doi.org/10.17269/cjph.103.3096
Levy AR, O’Brien BJ, Sellors C et al (2003) Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10:67–71
Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM (2011) Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int 22:1335–1342. https://doi.org/10.1007/s00198-010-1329-8
Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can
Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T (2009) Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD 6:388–394. https://doi.org/10.1080/15412550903140865
Hux JE, Ivis F, Flintoft V, Bica A (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:512–516. https://doi.org/10.2337/diacare.25.3.512
Tu K, Campbell NR, Chen Z-L, Cauch-Dudek KJ, McAlister F (2007) Accuracy of administrative databases in identifying patients with hypertension. Open Med 1:e18–e26
Widdifield J, Bombardier C, Bernatsky S, Paterson JM, Green D, Young J, Ivers N, Butt DA, Jaakkimainen RL, Thorne JC, Tu K (2014) An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance. BMC Musculoskelet Disord 15:216. https://doi.org/10.1186/1471-2474-15-216
Benchimol EI, Guttmann A, Mack DR, Nguyen GC, Marshall JK, Gregor JC, Wong J, Forster AJ, Manuel DG (2014) Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. J Clin Epidemiol 67:887–896. https://doi.org/10.1016/j.jclinepi.2014.02.019
Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T (2009) Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 16:183–188. https://doi.org/10.1155/2009/963098
Jaakkimainen RL, Bronskill SE, Tierney MC, Herrmann N, Green D, Young J, Ivers N, Butt D, Widdifield J, Tu K (2016) Identification of physician-diagnosed Alzheimer’s disease and related dementias in population-based administrative data: a validation study using family physicians’ electronic medical records. J Alzheimers Dis 54:337–349. https://doi.org/10.3233/JAD-160105
Iskander C, McArthur E, Nash DM, Gandhi-Banga S, Weir MA, Muanda FT, Garg AX (2019) Identifying Ontario geographic regions to assess adults who present to hospital with laboratory-defined conditions: a descriptive study. CMAJ Open 7:E624–E629. https://doi.org/10.9778/cmajo.20190065
CKD Evaluation and Management – KDIGO. https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed 24 Apr 2020
Burden AM, Paterson JM, Gruneir A, Cadarette SM (2015) Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf 24:67–74. https://doi.org/10.1002/pds.3718
Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38:1228–1234
Jamal SA, Ljunggren Ö, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835. https://doi.org/10.1002/jbmr.403
Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y (2017) Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol 18:66. https://doi.org/10.1186/s12882-017-0478-9
Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503–508. https://doi.org/10.1359/jbmr.070112
Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523. https://doi.org/10.1016/S2213-8587(17)30138-9
AMGEN Denosumab. https://www.amgen.ca/products/~/media/1E79AEE7D94340DF88C3D97F5BB897C3.ashx Accessed 20 June 2020
Miller PD (2011) The kidney and bisphosphonates. Bone 49:77–81. https://doi.org/10.1016/j.bone.2010.12.024
Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75–85. https://doi.org/10.1016/8756-3282(95)00445-9
Jaglal SB, Carroll J, Hawker G et al (2003) How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can Fam Physician 49
Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190. https://doi.org/10.1111/j.1525-139X.2007.00271.x
CKD-Mineral and Bone Disorder (CKD-MBD) – KDIGO. https://kdigo.org/guidelines/ckd-mbd/. Accessed 24 Apr 2020
Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L, Bayly J (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31:533–545. https://doi.org/10.1007/s00198-019-05228-8
Fardellone P, Lello S, Cano A, de Sá Moreira E, Watanabe de Oliveira R, Julian GS, Tang B (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576–1588. https://doi.org/10.1016/j.clinthera.2019.05.001
Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin M, Brekke L, Erdmann M, Walker V, Adachi JD (2015) Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Curr Med Res Opin 31:1391–1401. https://doi.org/10.1185/03007995.2015.1053049
Freemantle N, Satram-Hoang S, Tang E-T et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317–326. https://doi.org/10.1007/s00198-011-1780-1
Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022. https://doi.org/10.4065/81.8.1013
Adachi JD, Josse RG, Russell RGG (2011) If you don’t take it - it can’t work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag 7:181–198. https://doi.org/10.2147/TCRM.S17513
Carls GS, Tuttle E, Tan R-D, Huynh J, Yee J, Edelman SV, Polonsky WH (2017) Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 40:1469–1478. https://doi.org/10.2337/dc16-2725
Sørensen HT, Lash TL, Rothman KJ (2006) Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44:1075–1082. https://doi.org/10.1002/hep.21404
Knudsen JS, Thomsen RW, Pottegård A, Knop FK, Sørensen HT (2018) Differences between randomized clinical trial patients and real-world initiators of the glucagon-like peptide 1 receptor agonist liraglutide. Diabetes Care 41:e133–e135. https://doi.org/10.2337/dc18-0999
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. https://doi.org/10.1056/NEJMoa0809493
Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13:33. https://doi.org/10.1007/s11657-018-0439-3
Zhang J, Yun H, Wright NC, Kilgore M, Saag KG, Delzell E (2011) Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. Curr Rheumatol Rep 13:273–282. https://doi.org/10.1007/s11926-011-0168-8
Burden AM, Tadrous M, Calzavara A, Cadarette SM (2015) Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int 26:1525–1533. https://doi.org/10.1007/s00198-014-3023-8
Acknowledgments
The authors thank IMS Brogan Inc. for use of their Drug Information Database.
Funding
This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). It was conducted at ICES Western, which receives core funding from the Academic Medical Organization of Southwestern Ontario (AMOSO), the Schulich School of Medicine and Dentistry (SSMD), Western University, and the Lawson Health Research Institute (LHRI). Dr. K. Clemens received financial support to conduct this study from the Academic Medical Organization of Southwestern Ontario’s Opportunities Fund, and the Department of Medicine at Western University. Parts of this material are based on data and information compiled and provided by the MOHLTC and CIHI. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement by ICES, AMOSO, SSMD, LHRI, or the MOHLTC is intended or should be inferred.
Author information
Authors and Affiliations
Contributions
KC conceptualized the study, contributed to the design, and interpreted results, and she drafted the manuscript. AO contributed to the design of the study, conducted the analysis, and interpreted results, and she reviewed the manuscript critically. NJ contributed to the design and interpreted results, and she critically reviewed the manuscript. JT contributed to the design of the study and result interpretation, and she reviewed the manuscript critically. TK contributed to the design of the study and result interpretation, and he reviewed the manuscript critically. All authors approved the final version to be published.
Corresponding author
Ethics declarations
Conflicts of interest
KC received a research award that was sponsored in part by Astra Zeneca. She has attended Merck sponsored medical conferences. She has received honoraria for delivering Certified Medical Education talks on diabetes from Sutherland Global Services Canada ULC and the Toronto Ontario Knowledge Translation Working Group Inc. TK has attended Merck sponsored conferences. He has received honoraria from Sutherland Global Services Canada ULC, Novo Nordisk Canada, Abbott, Astra Zeneca, Valeant, the Canadian Medical and Surgical Knowledge Translation Research Group, Boehringer Ingelheim, and Amgen. There are no other conflicts of interest to disclose.
Ethics approval
ICES is an independent, non-profit research institute whose legal status under section 45 of Ontario’s Personal Health Information Protection Act (PHIPA) allows it to collect and analyze health care and demographic data, without REB approval or informed consent from participants, for health system evaluation and improvement.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Code availability
Please see the Online Resource.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 58 kb).
Rights and permissions
About this article
Cite this article
Clemens, K.K., Jeyakumar, N., Ouédraogo, A.M. et al. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study. Arch Osteoporos 15, 133 (2020). https://doi.org/10.1007/s11657-020-00796-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11657-020-00796-3